Tegsedi Approved in EU to Treat FAP Patients with Stage 1 or 2 Polyneuropathy
The European Commission (EC) has approved Tegsedi (inotersen), by Akcea Therapeutics and Ionis Pharmaceuticals, to treat stage 1 or 2 polyneuropathy in adults with hereditary transthyretin amyloidosis (hATTR). The approval — in the form of marketing authorization — comes on the heels of a positive recommendation by the…